Landos Pipeline Focused on Novel, Immunometabolic Targets

CandidateIndicationIndiPreclinicalPrePre-IndPre-IndPhase IPh IPhase IIPh IIPhase IIIPh III
NLRX1 Pathway
NX-13
CandidateIndicationIndiPreclinicalPrePre-IndPre-IndPhase IPh IPhase IIPh IIPhase IIIPh III
NX-13Ulcerative Colitis
Ulcerative Colitis
Phase 2 Topline Data 4Q24
Crohn's Diease
Crohn's Diease
Phase 2 Ready
LABP-66
CandidateIndicationIndiPreclinicalPrePre-IndPre-IndPhase IPh IPhase IIPh IIPhase IIIPh III
LABP-66Multiple Sclerosis
Multiple Sclerosis
Alzheimer's Disease
Alzheimer's Disease
LAPB-73
CandidateIndicationIndiPreclinicalPrePre-IndPre-IndPhase IPh IPhase IIPh IIPhase IIIPh III
LAPB-73Asthma
Asthma
COPD
COPD
PLXDC2 Pathway
LABP-69
CandidateIndicationIndiPreclinicalPrePre-IndPre-IndPhase IPh IPhase IIPh IIPhase IIIPh III
LABP-69Rheumatoid Arthritis
Rheumatoid Arthritis
Diabetic Nephropathy
Diabetic Nephropathy
Note: The Company is focused on advancing NX-13 clinical development in UC; Development and potential commercialization rights of NX-13 in China and select Asian markets licensed to LianBio; Research collaboration with Johns Hopkins University School of Medicine focused on advancing LABP-66 as a potential oral, once-daily therapy for MS and other disorders.

Learn More About Our Solution For Ulcerative Colitis

NX-13 Modulates Epithelial Integrity and Mucosal Immune Responses in the Gastrointestinal Tract

NX-13 is a potentially first-in-class novel, gut-selective, once-daily, oral therapeutic candidate that targets NLRX1 (NOD-like receptor X1), a mitochondria-associated receptor that has been associated with the modulation of inflammatory cytokines for UC.

In August 2022, the Company reported positive top-line results from a NX-13 Phase 1b trial, demonstrating a favorable safety and tolerability profile in UC patients across a range of once-daily doses. Results also indicated promising early signals of clinical improvement as soon as 2 weeks in patients’ symptoms and four weeks by endoscopy in exploratory endpoints.

In April 2023, we initiated the NEXUS, Phase 2 proof-of-concept trial to evaluate the safety, efficacy and pharmacokinetics in patients with moderate to severe UC. The NEXUS trial is dose-ranging, blinded, placebo-controlled and statistically powered.

The Company expects to report topline results from the NEXUS trial by the fourth quarter of 2024.

The NX-13 Phase 1b study was not powered for exploratory endpoints. Results are hypothesis generating only.

NX-13, an oral NLRX1 agonist for the treatment of ulcerative colitis and Crohn’s disease
NX-13 targets the NLRX1 pathway to induce anti-inflammatory effects in CD4+ T cells and other immune cells in the gastrointestinal tract. As a result, NX-13 has the potential to modulate epithelial integrity, host-microbiome interactions and mucosal immune responses.